-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Transdermal drug delivery (TDDS) refers to a drug delivery method in which the drug is coated or affixed to the surface of the skin, which becomes another route of administration after oral administration and injection, so that the drug can be administered at a constant rate (or near constant rate) through the skin and into the systemic circulation to produce systemic or local therapeutic effec.
Transdermal drug delivery systems are suitable for the treatment of various diseases, including Parkinson's, Alzheimer's, depression, schizophrenia, inflammatory pain, e.
At the same time, with the accelerated aging of the population, pain management is expected to become the market for transdermal drug delivery systems fast-growing application are.
According to the forecast of relevant institutions, the global transdermal drug delivery market will reach 45 billion yuan by 2024, and the global transdermal drug delivery system market is expected to reach 200 billion yuan in 202At present, the companies involved in transdermal drug delivery systems in the global market mainly include GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Mylan Pharmaceuticals, Hisamitsu Pharmaceuticals, and Johnson & Johns.
In the domestic market, Hunan Jiudian, Beijing Zizhu, Henan Lingrui, Zhejiang Asia Pacific, and Liansheng Pharmaceutical also participated in the transdermal drug delivery system mark.
Among them, Liansheng Pharmaceuticals strategically focuses on transdermal drug delivery technology produc.
It has jointly established a transdermal preparation sub-center with the National Engineering Research Center for Pharmaceutical Preparations, and has invested heavily in the development of a new generation of sustained and controlled-release transdermal preparations in vitro to achieve more optimal delive.
drug control syst.
At present, the company is developing 4 new transdermal drug delivery products and a global innovative cardiovascular and cerebrovascular drug, and more than 3 innovative products are planned in the project initiation and research sta.
It is reported that on July 21, the Liansheng Pharmaceutical Intelligent Manufacturing Center officially started construction in Zunyi City, Guizhou Provin.
The planned and designed building area of the project is 46,000 square meters, the budget investment is 450 million yuan, and the annual production capacity is designed to be greater than 2 billion pieces/paste/ye.
In addition, Hanyu Pharmaceutical also participated in the development of transdermal drug delivery syste.
In January this year, it held a cloud signing ceremony with Suzhou Yuefuda Medical Technology .
, L.
, a subsidiary of MicroPort Group, to jointly invest in the establishment of a joint venture company for pharmaceutical equipment and give full play to their respective With the advantages and resources in the fields of transdermal drug delivery systems, new drug development and pharmaceutical research, we will realize complementary advantages and carry out in-depth cooperation in the field of polypeptide microneedle transdermal drug delive.
According to the industry, transdermal drug delivery technology, as one of the important drug-carrying technologies for the development of new formulations, has shown attractive prospects in practi.
In the future, with the improvement of medical level and the change of concept, the market size of China's transdermal preparations is expected to continue to expand, thereby promoting the development of China's transdermal preparation indust.
For example, with the rapid increase in volume of Loxoprofen Sodium Gel Ointment, Jiudian Pharmaceutical has gradually increased the proportion of the company's preparation business reven.
Analysts said that in the medium and long term, transdermal drug delivery represented by Loxoprofen Sodium Gel Ointment will gradually increa.
Pharmaceutical preparations will drive the rapid growth of the company's performan.
It is reported that in addition to loxoprofen sodium gel ointment, Jiudian Pharmaceutical currently has a number of transdermal drugs in different stag.
With its rich product line, it is expected to occupy an important position in the field of transdermal drug delive.
Industry insiders said that although transdermal delivery is challenging, compared with oral, intravenous or enteral methods, transdermal delivery has the advantages of flexible dosing, ease of use, and improved patient complian.
Therefore, the research of transdermal drug delivery system has always been a technology of high concern in the indust.
On the whole, the development of China's transdermal drug delivery system industry still has room for considerable developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Transdermal drug delivery systems are suitable for the treatment of various diseases, including Parkinson's, Alzheimer's, depression, schizophrenia, inflammatory pain, e.
At the same time, with the accelerated aging of the population, pain management is expected to become the market for transdermal drug delivery systems fast-growing application are.
According to the forecast of relevant institutions, the global transdermal drug delivery market will reach 45 billion yuan by 2024, and the global transdermal drug delivery system market is expected to reach 200 billion yuan in 202At present, the companies involved in transdermal drug delivery systems in the global market mainly include GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Mylan Pharmaceuticals, Hisamitsu Pharmaceuticals, and Johnson & Johns.
In the domestic market, Hunan Jiudian, Beijing Zizhu, Henan Lingrui, Zhejiang Asia Pacific, and Liansheng Pharmaceutical also participated in the transdermal drug delivery system mark.
Among them, Liansheng Pharmaceuticals strategically focuses on transdermal drug delivery technology produc.
It has jointly established a transdermal preparation sub-center with the National Engineering Research Center for Pharmaceutical Preparations, and has invested heavily in the development of a new generation of sustained and controlled-release transdermal preparations in vitro to achieve more optimal delive.
drug control syst.
At present, the company is developing 4 new transdermal drug delivery products and a global innovative cardiovascular and cerebrovascular drug, and more than 3 innovative products are planned in the project initiation and research sta.
It is reported that on July 21, the Liansheng Pharmaceutical Intelligent Manufacturing Center officially started construction in Zunyi City, Guizhou Provin.
The planned and designed building area of the project is 46,000 square meters, the budget investment is 450 million yuan, and the annual production capacity is designed to be greater than 2 billion pieces/paste/ye.
In addition, Hanyu Pharmaceutical also participated in the development of transdermal drug delivery syste.
In January this year, it held a cloud signing ceremony with Suzhou Yuefuda Medical Technology .
, L.
, a subsidiary of MicroPort Group, to jointly invest in the establishment of a joint venture company for pharmaceutical equipment and give full play to their respective With the advantages and resources in the fields of transdermal drug delivery systems, new drug development and pharmaceutical research, we will realize complementary advantages and carry out in-depth cooperation in the field of polypeptide microneedle transdermal drug delive.
According to the industry, transdermal drug delivery technology, as one of the important drug-carrying technologies for the development of new formulations, has shown attractive prospects in practi.
In the future, with the improvement of medical level and the change of concept, the market size of China's transdermal preparations is expected to continue to expand, thereby promoting the development of China's transdermal preparation indust.
For example, with the rapid increase in volume of Loxoprofen Sodium Gel Ointment, Jiudian Pharmaceutical has gradually increased the proportion of the company's preparation business reven.
Analysts said that in the medium and long term, transdermal drug delivery represented by Loxoprofen Sodium Gel Ointment will gradually increa.
Pharmaceutical preparations will drive the rapid growth of the company's performan.
It is reported that in addition to loxoprofen sodium gel ointment, Jiudian Pharmaceutical currently has a number of transdermal drugs in different stag.
With its rich product line, it is expected to occupy an important position in the field of transdermal drug delive.
Industry insiders said that although transdermal delivery is challenging, compared with oral, intravenous or enteral methods, transdermal delivery has the advantages of flexible dosing, ease of use, and improved patient complian.
Therefore, the research of transdermal drug delivery system has always been a technology of high concern in the indust.
On the whole, the development of China's transdermal drug delivery system industry still has room for considerable developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
